Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, PK and PD of AB-101, an Oral PD-L1 Inhibitor, in Healthy Subjects and Subjects With Chronic HBV Infection.

NCT05960240 is registered in ClinicalTrials.gov with Arbutus Biopharma Corporation as lead sponsor.

NCT NCT05960240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05960240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, PK and PD of AB-101, an Oral PD-L1 Inhibitor, in Healthy Subjects and Subjects With Chronic HBV Infection.
Lead sponsor
Arbutus Biopharma Corporation
Phase
Phase 1
Overall status
Completed
Start date
August 30, 2023
Completion date
February 9, 2026
Enrollment
128 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b